American Diabetes Association:  American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference of antipsychotic drugs and obesity and diabetes.  Diabetes Care   2004; 27:598–600http://www.ncbi.nlm.nih.gov/pubmed/14747245
 American Psychiatric Association:  Practice Guideline for the Treatment of Patients With Major Depressive Disorder , 3rd Edition.  Arlington, VA,  American Psychiatric Association,  2010. Available at: http://psychiatryonline.org/data/Books/prac/PG_Depression3rdEd.pdf
Athanasiou  MC;  Dettling  M;  Cascorbi  I;  Mosyagin  I;  Salisbury  BA;  Pierz  KA;  Zou  W;  Whalen  H;  Malhotra  AK;  Lencz  T;  Gerson  SL;  Kane  JM;  Reed  CR:  Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapineinduced agranulocytosis.  J Clin Psychiatry   2011; 72:458–463
Ballon  JS;  Lieberman  JA:  Advances in the management of treatment-resistant schizophrenia.  Focus   2010; 8:475–487
Biederman  J;  Monuteaux  MC;  Spencer  T;  Wilens  TE;  MacPherson  HA;  Faraone  SV:  Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study.  Am J Psychiatry   2008; 165:597–603. Focus 2008; 6:358–365
Birmaher  B;  Brent  D;  Bernet  W;  Bukstein  O;  Walter  H;  Benson  RS;  Chrisman  A;  Farchione  T;  Greenhill  L;  Hamilton  J;  Keable  H;  Kinlan  J;  Schoettle  U;  Stock  S;  Ptakowski  KK;  Medicus  J:  AACAP Work Group on Quality Issues: Practice parameter for the assessment and treatment of children and adolescents with depressive disorders.  J Am Acad Child Adolesc Psychiatry   2007; 46:1503–1526. Focus 2008; 6:379–400
Buchanan  RW;  Kreyenbuhl  J;  Kelly  DL;  Noel  JM;  Boggs  DL;  Fischer  BA;  Himelhoch  S;  Fang  B;  Peterson  E;  Aquino  PR;  Keller  W:  Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.  Schizophr Bull   2010; 36:71–93
Buckley  PF;  Foster  A;  Miller  B:  Schizophrenia host vulnerability and risk of metabolic disturbances during treatment with antipsychotics.  Focus   2008; 6:172–179
Burt  VK;  Hedrick  VC (ed):  Clinical Manual of Women’s Mental Health .  Washington, DC,  American Psychiatric Publishing,  2005, pp 150
Casadio  P;  Fernandes  C;  Murray  RM;  Di Forti  M:  Cannabis use in young people: the risk for schizophrenia.  Neurosci Biobehav Rev   2011; 35:1779–1787
Citrome  L:  Role of sublingual asenapine in treatment of schizophrenia.  Neuropsychiatr Dis Treat   2011; 7:325–339
Cohen  LS;  Friedman  JM;  Jefferson  JW;  Johnson  EM;  Weiner  ML:  A reevaluation of risk of in utero exposure to lithium.  JAMA   1994; 271:146–150
Correll  CU;  Manu  P;  Olshanskiy  V;  Napolitano  B;  Kane  JM;  Malhotra  AK:  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.  JAMA   2009; 302:1765–1773
Coryell  W:  The search for improved antidepressant strategies: is bigger better? Am J Psychiatry   2011; 168:664–666
Cuijpers  P;  van Straten  A;  Andersson  G;  van Oppen  P:  Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. J Consult Clin Psychol 2008; 76:909–922.  Focus   2010; 8:75–91
Cunningham  J;  Yonkers  KA;  O’Brien  S;  Eriksson  E:  Update on research and treatment of premenstrual dysphoric disorder.  Harv Rev Psychiatry   2009; 17:120–137
 Diagnostic and Statistical Manual of Mental Disorders:  DSM-IV-TR , Fourth Edition, Text Revision.  Washington, DC,  American Psychiatric Association,  2000, pp 422
Dias  RS;  Lafer  B;  Russo  C;  Del Debbio  A;  Nierenberg  AA;  Sachs  GS;  Joffe  H:  Longitudinal follow-up of bipolar disorder in women with premenstrual exacerbation: findings from STEP-BD.  Am J Psychiatry   2011; 168:386–394
Dickerson  FB;  Lehman  AF:  Evidence-based psychotherapy for schizophrenia: 2011 update.  J Nerv Ment Dis   2011; 199:520
526. Reprinted in FOCUS 2012; 10:217-225.
Dixon  L;  Perkins  D;  Calmes  C: Guideline Watch (September 2009): Practice Guideline for the Treatment of Patients With Schizophrenia. Arlington, VA: American Psychiatric Association,  2009. Available from: http://www.psychiatryonline.com/pracGuide/PracticePDFs/Schizophrenia_Guideline%20Watch.pdf.
Dulcan  MK (ed):  Dulcan’s Textbook of Child and Adolescent Psychiatry .  Washington, DC,  American Psychiatric Publishing,  2010
34067–9 Duvvuri V, Kaye WH: Anorexia nervosa clinical synthesis. Focus 2009; 7:459-460 Einarson A, Boskovic R: Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009; 15:183–192
Emslie  GJ;  Kennard  BD;  Mayes  TL;  Nightingale-Teresi  J;  Carmody  T;  Hughes  CW;  Rush  AJ;  Tao  R;  Rintelmann  JW:  Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.  Am J Psychiatry   2008; 165:459
467. Reprinted in FOCUS 2008; 6:355-356
Fabrazzo  M;  La Pia  S;  Monteleone  P;  Mennella  R;  Esposito  G;  Pinto  A;  Maj  M:  Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time-and dose-dependent manner.  J Clin Psychopharmacol   2000; 20:708–710
 FDA:  Risk of oral birth defects in children born to mothers taking topiramate . http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm245594.htm.
Fitelson  E;  Kim  S;  Baker  AS;  Leight  K:  Treatment of postpartum depression: clinical, psychological and pharmacological options.  Int J Womens Health   2010; 3:1–14
Freeman  EW;  Rickels  K;  Sondheimer  SJ;  Polansky  M;  Xiao  S:  Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder.  Am J Psychiatry   2004; 161:343–351
Galanter  M;  Kleber  HD (eds):  The American Psychiatric Publishing Textbook of Substance Abuse Treatment , 4th ed.  Washington, DC,  American Psychiatric Publishing,  2008.
Gaynes  BN;  Warden  D;  Trivedi  MH;  Wisniewski  SR;  Fava  M;  Rush  AJ:  What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression.  Psychiatr Serv   2009; 60:1439–1445
 GlaxoSmithKline: Change in the Pregnancy subsection of the PRECAUTIONS section in the labels for PAXIL (paroxetine HCl) and PAXIL CR (paroxetine HCl) Controlled-Release Tablets, Sept  2005. Accessed on August 10, 2011 from: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM164865.pdf
Goldstein  BI:  Recent progress in understanding pediatric bipolar disorder.  Arch Pediatr Adolesc Med   2012; 166:362–371
Greenfield  SF;  Back  SE;  Lawson  K;  Brady  KT:  Substance abuse in women.  Psychiatr Clin North Am   2010; 33:339–355
Haas  SJ;  Hill  R;  Krum  H;  Liew  D;  Tonkin  A;  Demos  L;  Stephan  K;  McNeil  J:  Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003.  Drug Saf   2007; 30:47–57
Haddad  PM;  Anderson  IM:  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.  Drugs   2002; 62:1649–1671
Haddad  PM;  Sharma  SG:  Adverse effects of atypical antipsychotics: differential risk and clinical implications.  CNS Drugs   2007; 21:911–936
Hales  RE;  Yudofsky  SC;  Gabbard  GO (eds): The American Psychiatric Publishing Textbook of Psychiatry, 5th ed. Washington, DC, American Psychiatric Publishing,  2008.
Jaquenoud Sirot  E;  Knezevic  B;  Morena  GP;  Harenberg  S;  Oneda  B;  Crettol  S;  Ansermot  N;  Baumann  P;  Eap  CB:  ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.  J Clin Psychopharmacol   2009; 29:319–326
Jefferson  JW:  Lamotrigine in psychiatry: pharmacology and therapeutics.  CNS Spectr   2005; 10:224–232
Kane  JM:  New-onset schizophrenia: pharmacologic treatment.  Focus   2008; 6:167–171
Kar  N:  Cognitive behavioral therapy for the treatment of post-traumatic stress disorder: a review.  Neuropsychiatr Dis Treat   2011; 7:167–181
Kreyenbuhl  J;  Marcus  SC;  West  JC;  Wilk  J;  Olfson  M:  Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv   2007; 58:983–990. Focus 2008; 6:212–220
Leibenluft  E;  Rich  BA:  Pediatric bipolar disorder.  Annu Rev Clin Psychol .  2008; 4:163–87. Focus 2008; 6:334
Louik  C;  Lin  AE;  Werler  MM;  Hernández-Díaz  S;  Mitchell  AA:  First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.  N Engl J Med   2007; 356:2675–2683
Ma  J;  Alvir  J;  Lieberman  JA;  Safferman  AZ;  Schwimmer  JL;  Schaaf  JA:  Clozapine-induced agranulocytosis–incidence and risk factors in the United States.  N Engl J Med   1993; 329:162–167
Madaan  V:  Assessment of panic disorder across the life span.  Focus   2008; 6:439
Markowitz  JC:  The clinical conduct of interpersonal psychotherapy.  Focus   2006; 4:179–184
Martin  A;  Volkmar  FR (ed):  Lewis’s Child and Adolescent Psychiatry , 4th ed.  Philadelphia,  Lippincott, Williams & Wilkins,  2007
Masi  G;  Liboni  F;  Brovedani  P:  Pharmacotherapy of major depressive disorder in adolescents.  Expert Opin Pharmacother   2010
11. : 375–386 McGavin JK, Goa KL:  Aripiprazole. CNS Drugs 2002; 16:779–786, discussion 787–788 Menon SJ: Psychotropic medication during pregnancy and lactation.  Arch Gynecol Obstet   2008; 277:1–13
Morrell  MJ;  Hayes  FJ;  Sluss  PM;  Adams  JM;  Bhatt  M;  Ozkara  C;  Warnock  CR;  Isojärvi  J:  Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine.  Ann Neurol   2008; 64:200–211
Murray  RM;  Van Os  J:  Predictors of outcome in schizophrenia.  J Clin Psychopharmacol   1998; 18(Suppl 1):2S–4S
Nemeroff  CB:  Recent findings in the pathophysiology of depression.  Focus   2008; 6:3–14
Norman  RM;  Manchanda  R;  Malla  AK;  Harricharan  R;  Northcott  S:  The significance of family history in first-episode schizophrenia spectrum disorder.  J Nerv Ment Dis   2007; 195:846–852
Oldham  JM;  Skodol  AE;  Bender  DS (ed):  Essentials of Personality Disorders .  Washington, DC,  American Psychiatric Publishing,  2009
Package insert for olanzapine extended release injectable suspension. Eli Lilly and Company. Revision July 5,  2011. http://pi.lilly.com/us/zyprexa-pi.pdf
Payne  JL:  Antidepressant use in the postpartum period: practical considerations.  Am J Psychiatry   2007; 164:1329–1332
Pearlstein  T;  Steiner  M:  Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci 2008; 33:291-301.  Focus   2012; 10:90–101
Pinkerton  JV;  Stovall  DW;  Kightlinger  RS:  Advances in the treatment of menopausal symptoms.  Womens Health (Lond Engl)   2009; 5:361–384, quiz 383–384
Pliszka  SR;  Crismon  ML;  Hughes  CW;  Corners  CK;  Emslie  GJ;  Jensen  PS;  McCracken  JT;  Swanson  JM;  Lopez  M:  Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder: The Texas Children’s Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.  J Am Acad Child Adolesc Psychiatry   2006; 45:642–657. Reprinted in FOCUS 2008; 6:401–426.
Pliszka  S  et al.:  Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Amer Acad Child Adolesc Psychiatry 2007; 46:894–921.  Focus   2008; 6:401–426
 Practice Guideline for the Treatment of Patients With Bipolar Disorder:  2002, in  American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders, Compendium 2004 , 2nd ed.  Washington, DC,  APA,  2004, pp 572–573. [Reprinted in FOCUS 2003; 1:64–110 ] [pp 91–92] [ Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition:] Arlington VA: American Psychiatric Association, 2004. http://psychiatryonline.org/content.aspx?bookid=28&sectionid=1665359
 Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder.  J Am Acad Child Adolesc Psychiatry   2010; 49:421–424
Raedler  TJ:  Cardiovascular aspects of antipsychotics.  Curr Opin Psychiatry   2010; 23:574–581
Rathod  S;  Kingdon  D;  Weiden  P;  Turkington  D:  Cognitive-behavioral therapy for medication-resistant schizophrenia: a review.  Journal of Psychiatric Practice   2008; 14:22–33. Focus 2010; 8:626–637
Rettew  DC;  Stanger  C;  McKee  L;  Doyle  A;  Hudziak  JJ:  Interactions between child and parent temperament and child behavior problems. Compr Psychiatry 2006; 47:412–420.  Focus   2010; 8:282
Robinson  GE:  Psychopharmacology in pregnancy and postpartum.  Focus   2012; 10:3–14
Ronaldson  KJ;  Fitzgerald  PB;  Taylor  AJ;  Topliss  DJ;  McNeil  JJ:  A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls.  Aust N Z J Psychiatry   2011; 45:458–465
Rush  AJ;  Trivedi  MH;  Stewart  JW;  Nierenberg  AA;  Fava  M;  Kurian  BT;  Warden  D;  Morris  DW;  Luther  JF;  Husain  MM;  Cook  IA;  Shelton  RC;  Lesser  IM;  Kornstein  SG;  Wisniewski  SR:  Combining Medications to Enhance Depression Outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.  Am J Psychiatry   2011; 168:689–701
Rush  AJ;  Warden  D;  Wisniewski  SR;  Fava  M;  Trivedi  MH;  Gaynes  BN;  Nierenberg  AA:  STAR*D: revising conventional wisdom.  CNS Drugs   2009; 23:627–647
Sabers  A;  Buchholt  JM;  Uldall  P;  Hansen  EL:  Lamotrigine plasma levels reduced by oral contraceptives.  Epilepsy Res   2001; 47:151–154
Sadock  BJ;  Sadock  VA (ed):  Kaplan and Sadock’s Synopsis of Psychiatry, 10th ed.  Philadelphia,  Lippincott Williams & Wilkins,  2007
Schatzberg  AF;  Cole  JO;  DeBattista  C:  Manual of Clinical Psychopharmacology , 7th ed.  Washington, DC,  American Psychiatric Publishing,  2010
Schatzberg  AF;  Nemeroff  CB (eds):  The American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed.  Washington, DC,  American Psychiatric Publishing,  2009.
Schechter  DS;  Willheim  E:  Disturbances of attachment and parental psychopathology in early childhood.  Child Adolesc Psychiatr Clin N Am   2009; 18:665–686
Seeman  MV:  Gender differences in the prescribing of antipsychotic drugs.  Am J Psychiatry   2004; 161:1324–1333. Reprinted in Focus 2006; 4:115–124
 Selegiline transdermal system package insert. Available from http://packageinserts.bms.com/pi/pi_emsam.pdf. Accessed on December 26, 2011
Simon  GE;  Savarino  J:  Suicide attempts among patients starting depression treatment with medications or psychotherapy.  Am J Psychiatry   2007; 164:1029–1034. Reprinted in FOCUS 2008; 6:80–85
Sindrup  SH;  Brøsen  K:  The pharmacogenetics of codeine hypoalgesia.  Pharmacogenetics   1995; 5:335–346
Soares  CN;  Murray  BJ:  Sleep disorders in women: clinical evidence and treatment strategies.  Psychiatr Clin North Am   2006; 29:1095–1113[abstract xi]
Spina  E;  Santoro  V;  D’Arrigo  C:  Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.  Clin Ther   2008; 30:1206–1227
Spina  E;  Trifirò  G;  Caraci  F:  Clinically significant drug interactions with newer antidepressants.  CNS Drugs   2012; 26:39–67
Spinelli  MG:  Postpartum psychosis: detection of risk and management.  Am J Psychiatry   2009; 166:405–408
Stroup  TS;  McEvoy  JP;  Ring  KD;  Hamer  RH;  LaVange  LM;  Swartz  MS;  Rosenheck  RA;  Perkins  DO;  Nussbaum  AM;  Lieberman  JA:  Schizophrenia Trials Network: A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).  Am J Psychiatry   2011; 168:947–956
Sullivan  PF;  Neale  MC;  Kendler  KS:  Genetic epidemiology of major depression: review and meta-analysis.  Am J Psychiatry   2000; 157:1552–1562
Suri  R;  Altshuler  L:  Postpartum depression: Advances in recognition and treatment.  Focus   2012; 10:15–21
Tsoi  DT;  Porwal  M;  Webster  AC:  Interventions for smoking cessation and reduction in individuals with schizophrenia.  Cochrane Database Syst Rev   2010; (6):CD007253
Turkington  D;  Dudley  R;  Warman  DM;  Beck  AT:  Cognitive-behavioral therapy for schizophrenia: a review. Journal of Psychiatry Practice 2004; 10:5–16.  Focus   2006; 4:223–233
 U.S. Food and Drug Administration: FDA Executive Summary Prepared for the January 27-28, 2011 Meeting of the Neurological Devices Panel Meeting to Discuss the Classification of Electroconvulsive Therapy Devices (ECT). Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/NeurologicalDevicesPanel/UCM240933.pdf
Udechuku  A;  Nguyen  T;  Hill  R;  Szego  K:  Antidepressants in pregnancy: a systematic review.  Aust N Z J Psychiatry   2010; 44:978–996
 US Food and Drug Administration: Department of Health and Human Services: FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm.
Valentino  RM;  Foldvary-Schaefer  N:  Modafinil in the treatment of excessive daytime sleepiness.  Cleve Clin J Med   2007; 74:561–566, 568–571
 Vilazodone (Viibryd)—a new antidepressant.  Med Lett Drugs Ther   2011; 53:53–54
Vitiello  B;  Elliott  GR;  Swanson  JM;  Arnold  LE;  Hechtman  L;  Abikoff  H;  Molina  BS;  Wells  K;  Wigal  T;  Jensen  PS;  Greenhill  LL;  Kaltman  JR;  Severe  JB;  Odbert  C;  Hur  K;  Gibbons  R:  Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD.  Am J Psychiatry   2012; 169:167–177
Westphal  A;  Volkmar  FR:  An update on autism.  Focus   2008; 6:284–292
Wisner  KL;  Sit  DKY;  Hanusa  BH;  Moses-Kolko  EL;  Bogen  DL;  Hunker  DF  et al.:  Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166:557–566.  Focus   2009; 7:374–384
Yonkers KA, Vigod S, Ross LE: Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol 2011; 117:961–977 Reprinted in FOCUS Winter 2012; 10; 51–66
Yonkers KA, et al: The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Arlington, VA, American Psychiatric Association, 2009. Reprinted in Focus Winter 2012; 10:78–89
Ziprasidone Prescribing Information: Pfizer, Inc., Nov, 2009. http://labeling.pfizer.com/ShowLabeling.aspx?id=584